Industry Insider
Busting Drug Discovery Bottlenecks
February 7, 2013 4:35 pm | by Megean Schoenberg and Rudy Potenzone, PhD; PerkinElmer, Inc., Waltham, Mass. | Articles | CommentsDrug research scientists often face the challenge of juggling their own research and analytical needs with the needs of the larger institution. Research is variable, yet standardization often implies the need to conform to a process. Given these challenges, science needs a new approach for empowering scientists in drug discovery.
Instrument-driven
June 11, 2012 4:36 pm | by Rita Peters, Editorial Director | Articles | CommentsA recent survey of Drug Discovery & Development readers revealed what types of instruments and systems are behind the wheel of drug research programs.
Ensuring Quality for Container Closure Systems
March 13, 2012 2:45 pm | by Diane M. Paskiet, Associate Director, Scientific Affairs; West Pharmaceutical Services Inc., Lionville, Pa. | Articles | CommentsGMPs and other guidelines can help suppliers and pharmaceutical manufactures improve product quality, with greater efficiency and reliability.
Funding for HIV/AIDS Research: A Challenge for Small Pharma
March 9, 2012 12:02 pm | by Robert McNally, PhD, President and Chief Executive Officer, GeoVax Labs, Atlanta, Ga. | Articles | CommentsIn spite of the ongoing urgency to develop HIV/AIDS vaccines, various research groups and small biopharma companies around the globe are encountering challenges in raising the levels of funding that are necessary to sustain effective research and clinical trials.
Hitting Leadoff in Biotech
July 13, 2011 6:40 am | by Emily Walsh, PhD, Principal Consultant; Halloran Consulting Group, Waltham, Mass. | Articles | CommentsOften heard advice for the entrepreneurial set is: “Be a credible threat.” That of course is a tall order. The odds and costs are stark. Historically, only 1 in 10 lead candidates make it through to approval, and this number is likely to be lower in 2010. If this weren’t daunting enough, the failure-inclusive cost of developing that one drug is thought to be a billion dollars.
Principal Investigator System Enables CROs to Improve Bioanalytical Study Management
February 10, 2011 10:26 am | by Richard LeLacheur, Vice President, PharmaNet, Princeton, NJ | Articles | CommentsIn order to ensure smooth operation during bioanalytical studies, a novel model, where a principal investigator with direct control over the entire study is the core of the project, has been developed.
Effects of the Emerging Pharmaceutical R & D Model on Informatics
January 14, 2011 4:50 am | by Arjun Bedi, Global Managing Partner, Accenture Health & Life Sciences R&D Practice, Philadelphia, Pa. | Articles | CommentsThe need for pharmaceutical R&D organizations to manage expanding volumes of data crucial will require a change in focus and approach.
Immnotherapy Welcomes TLR7
October 7, 2008 9:41 am | by Steve Worland, PhD, President, Chief Executive Officer, and Director, Anadys Pharmaceuticals, San Diego, Calif. | Articles | CommentsResearchers attempting to establish immunotherapies have been challenged when dosing with TLR agonists. With a better understanding of how to optimize the schedule of administering TLR7 agonists in different disease states, they may be able to sculpt the immune response appropriately for different diseases.
Hot Jobs for a Cool Economy
August 11, 2008 11:05 am | by Peter Ferguson, President, Yoh Scientific and Michael Gamble, Director Strategic Sales, Health & Life Sciences, Yoh Scientific | Articles | CommentsIn these tough times, the biotech job market looks promising, if you know how to sell your skills.
The Race to the $1000 Genome: Sprinting Toward the Finish Line
July 9, 2008 11:31 am | by Patrice M. Milos, PhD, Vice President and Chief Scientific Officer, Helicos BioSciences Corporation | Articles | CommentsThe question of when it will be possible to sequence a human genome is being replaced by concerns whether the average consumer will choose to have his or her genome sequenced.
A Versatile Strategy
April 17, 2008 7:52 am | by Neil Kurtz, MD, President and Chief Executive Officer, TorreyPines Therapeutics, Inc., La Jolla, Calif. | Articles | CommentsFor small biopharmaceutical companies, the mechanism of action approach may build the most attractive pipeline.
Personal Dose: A New Direction and Profit Source?
November 30, 2007 12:51 pm | by Girish Malhotra, PE, President, EPCOT International, Pepper Pike, Ohio | Articles | CommentsWith $100 billion in patents expiring by 2011, pharmaceutical companies need new drug discovery and development routes. A "personal dose" model could be an alternative.
The Next Era of Gene Expression Tools
October 11, 2007 12:58 pm | by Bruce Silgmann, PhD, High Throughput Genomics | Articles | CommentsObstacles to measuring gene expression have hindered the impact of genomics on drug discovery and the life sciences.
Patents on a Budget: The Provisional Application
October 11, 2007 12:51 pm | by Richard Lebovitz, Millen, White, Zelano, and Branigan | Articles | CommentsPatents are the intellectual property currency of the world of commerce.
Bioinformatics Outstrips Info Technology
October 11, 2007 12:38 pm | by Michael Kane, PhD, Purdue University | Articles | CommentsIn addition to the growing amount of genomic data, the diversity of data types in the bioinformatics domain are also increasing, and systems biology efforts emerge to integrate genomic data with proteomic, ionomic, metabolomic, biochemical, and pharmacological data to study various fundamental aspects of living systems.
Integrate Integrative Biology?
October 11, 2007 11:38 am | by Ken Rubenstein, PhD, Lion Consulting Group | Articles | CommentsSystems biology underwent a dramatic renaissance in 2000.
Interdisciplinary Training in Bioinformatics, IT
October 11, 2007 8:40 am | by Michael Kane, PhD, Purdue University | Articles | CommentsInformation systems are the lifeblood of the new century.
Revitalizing the Peptide
September 20, 2007 11:03 am | by Rodney Lappe, PhD | Articles | CommentsResearchers seeking the "next generation" of therapeutics are taking novel—but undeniably risky approaches.
Biopharma’s Virtual Business Model
September 6, 2007 7:02 am | Articles | CommentsWilliam Porter Jr. At a Glance Title: Senior vice president, business development, Asia-Pacific Company: VDDI Pharmaceuticals, Brentwood, Tenn. Education: BS and MS, Michigan State University Background: Porter has more than 30 years experience in the biopharmaceutical industry, education, project management, and government relations.
RNAi Market Boosted by Price, Ease
September 6, 2007 7:02 am | Articles | CommentsRaju Adhikari, Mbiochem, DPhil At a Glance Title: Pharmaceutical-biotechnology industry analyst. Company: Frost & Sullivan Healthcare Practice, Europe. Education: First Class Masters degree, University of Oxford, UK; Doctorate in immunology, University of Oxford, UK.
Beyond Assay Development 101
September 6, 2007 7:01 am | Articles | CommentsRalph Garippa, PhD At a Glance Title: Research leader for Cell-based HTS and Robotics Company: Hoffmann-La Roche Inc., Discovery Technologies, Nutley, N.J. Education: PhD, pharmacology, Columbia University, New York; BS, biology, Fairleigh Dickinson University, Rutherford, N.J.
Assembly Line or Custom Design?
September 6, 2007 7:00 am | Articles | CommentsLisa Minor, PhD At a Glance Title: Principal scientist, vascular biology Company: Johnson & Johnson Pharmaceutical Research and Development, Springhouse, Pa. Education: PhD, biochemistry, Pennsylvania State University, State College, Pa.; BS, zoology/botany, Oregon State University, Corvallis, Ore.
Biomarkers Save Clinical Trial Costs
September 6, 2007 7:00 am | Articles | CommentsPhil Webster At a Glance Title: Pharma-biotech analyst for European Healthcare Practice Company: Frost & Sullivan
Reducing Health Risks of Drugs
September 6, 2007 6:58 am | Articles | CommentsThe problem of serious physical risks associated with pharmaceutical drugs is not going away.
Trial Data on the Hot Seat
September 6, 2007 6:58 am | Articles | CommentsThe pharmaceutical and biotechnology industries are on the hot seat when it comes to clinical trials...
